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Introduction
Inflammation, defined as the local recruitment and activa-
tion of leukocytes, is an essential component of the innate
immune response to pathogens and damaged cells. Con-
sequently, mouse and human genetic defects in leukocyte
recruitment manifest themselves as an increased frequency
and susceptibility to infection and/or as a failure to remove
degenerating tissues, such as the stump of a neonatal
umbilical cord [1]. The innate inflammatory response has
only a limited ability to distinguish normal from infected or
damaged cells. Consequently, injury to healthy bystander
cells at a site of inflammation is common. Moreover, unre-
solved inflammation can itself become a disease process, a
clear example being rheumatoid arthritis. Inhibition of
inflammation in such settings has become a primary goal of
therapy irrespective of the underlying cause of the disease.
For this reason, it is important to understand how inflamma-
tion develops and how it is regulated. In this chapter, I
describe how tumor necrosis factor (TNF), an important
mediator of innate inflammation, acts on vascular endothe-
lial cells (ECs) to promote the inflammatory response.
Historical background
A description of the inflammatory response to injured
tissues at the level of light microscopy was first made over
100 years ago [2]. In those pioneering studies, Cohnheim
noted that margination of leukocytes along the luminal
surface of the postcapillary venule is the prelude to extrava-
sation. Before the 1980s, these events were generally
interpreted as a response of circulating leukocytes to
chemoattractant substances elaborated within the tissue,
either by infectious microbes (e.g. N-formyl peptides) or by
the innate response (e.g. complement fragment C5a) [3].
Margination was explained by the observation that such
substances not only induced chemotaxis but also triggered
adhesion to endothelium, although the increase in adhe-
sion was usually quite small (not more than twofold) [4].
This model did not explain why superfusion of chemotactic
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substances does not cause circulating leukocytes to
adhere to endothelium until they reach the venules [5].
Endothelial-cell-based model of inflammation
A re-evaluation of this paradigm began in the mid 1980s
with the finding that exposure of ECs to cytokines, such as
IL-1 or TNF, caused the ECs to bind 20 to 40 times as
many leukocytes as untreated ECs, dwarfing the effects of
chemotaxins [6]. The change in EC adhesivity arose from
the induction of new surface proteins, collectively desig-
nated as endothelial leukocyte adhesion molecules
(ELAMs), that bind counter-receptor proteins expressed
on leukocytes [7]. Cytokine-treated ECs are also a source
of chemoattractant cytokines (chemokines) that contribute
to adhesion by activating the affinity of leukocyte counter-
receptors for ELAMs [7]. These observations, combined
with new experimental models such as parallel plate flow
chambers and ex vivo videomicroscopy, led to the current
multistep model of leukocyte recruitment centered on the
responses of the vascular ECs lining postcapillary venules
rather than on responses of leukocytes [8,9]. In brief,
resting ECs are now viewed as noninteractive with leuko-
cytes, so that random encounters with circulating white
cells are short-lived, leaving both cells unaltered. Microbes
and other inflammatory stimuli induce resident
macrophages to release cytokines such as TNF or IL-1,
which induce venular ECs to synthesize and express new
proteins on their luminal cell surface. Critically, cytokine-
treated ECs express several new ELAMS, namely
E-selectin and integrin-ligands such as intercellular
adhesion molecule-1 (ICAM-1) and vascular cell adhesion
molecule-1 (VCAM-1), that can interact with blood leuko-
cytes. (Mouse ECs, but not human ones, also upregulate
P-selectin in response to TNF or IL-1.) Cytokine-activated
ECs also synthesize, secrete, and display (in association
with cell-surface proteoglycans) chemokines on their
luminal surface. Circulating leukocytes that bump into
cytokine-activated ECs rapidly form low-affinity interac-
tions mediated by binding to E-selectin and/or VCAM-1.
Shear force, imparted by flowing blood, causes these
interactions to be rapidly broken, only to reform rapidly as
the leukocyte is displaced. Multiple iterations of these
processes results in rolling of the leukocyte on the EC
surface. Rolling, but not free-flowing, leukocytes
encounter and respond to the surface-displayed
chemokines, causing cell spreading and clustering of
surface integrins (such as LFA-1 and VLA-4) at the
contact area with the ECs. These leukocyte integrins are
the counter-receptors for ICAM-1 and VCAM-1 on ECs,
and enhanced interactions by clustered integrins produce
firm attachment to the ECs. Bound chemokines also stim-
ulate leukocyte chemokinesis, resulting in crawling on the
EC surface. As crawling leukocytes reach the junction
between ECs, they extravasate through the junction into
the tissue space, resulting in inflammation.
Several refinements of this EC-based model of inflamma-
tion are worth noting. One point involves the specialized
nature of venular ECs. Although ICAM-1 is upregulated by
TNF or IL-1 on essentially all ECs lining the microvascula-
ture, E-selectin and VCAM-1 are normally confined to ECs
of the postcapillary venule, the site of leukocyte rolling and
margination [10]. However, in certain disease states (e.g.
psoriasis), capillaries also may express these molecules,
and the pattern of leukocyte extravasation changes to
match that of expression of adhesion molecules [11]. In
addition, the patterns of adhesion molecule expression
(and chemokine expression) are dynamic. For example,
expression of E-selectin, associated with neutrophil
extravasation, peaks early (at 2–4 hours) after TNF addi-
tion, corresponding to the onset of neutrophil recruitment.
VCAM-1, which is more closely associated with binding of
mononuclear leukocytes, typically peaks at later times
(12–24 hours) after TNF addition, corresponding to the
onset of T-cell recruitment [12]. Finally, the EC response
to TNF can be modified by T-cell-derived cytokines. For
example, IFN-γ prolongs the expression of E-selectin [13],
whereas IL-4 suppresses the expression of E-selectin while
promoting that of VCAM-1 [14]. These alterations in the
EC surface produce corresponding changes in the nature
of the inflammatory leukocyte populations that are
recruited. Specifically, IFN-γ favors recruitment of leuko-
cytes associated with inflammation of the T-helper-1 type
(dependent on E-selectin), whereas IL-4 favors inflamma-
tion of the T-helper-2 type (independent of E-selectin) [15].
In other words, the spatial, temporal, and qualitative pat-
terns of EC adhesion molecule expression govern the loca-
tion, evolution, and nature of the inflammatory response.
The biochemistry of TNF signaling in
endothelial cells
A central role of TNF in inflammation has been established
by observations that many inflammatory reactions are
impaired in TNF or TNF-receptor (TNFR) knockout mice
[16] and that, in humans, TNF inhibitors (soluble receptors
or neutralizing antibodies) are effective anti-inflammatory
therapeutics [17]. As I have noted, proinflammatory
actions of TNF on ECs generally involve new protein syn-
thesis. In general, these changes are initiated by new gene
transcription [7]. Two specific transactivating (transcrip-
tion) factors, NF-κB and activator protein-1 (AP-1), are
essential (although probably not sufficient) for TNF induc-
tion of ELAMs [18]. The evidence for this conclusion is
that the E-selectin, ICAM-1, and VCAM-1 genes each
contain DNA sequences in their 5′ flanking regions that
bind various forms of NF-κB and AP-1 in electrophoretic-
mobility-shift assays and that mutations of these
sequences reduce TNF responses of transfected pro-
moter–reporter genes. In addition, transfection experi-
ments of wild-type and mutant forms of NF-κB and AP-1
subunits into cultured ECs can regulate in the expression
of E-selectin, ICAM-1, and VCAM-1.S111
An active area of research in the 1990s was the elucida-
tion of signaling pathways through which TNF could acti-
vate NF-κB and AP-1. Human ECs, like most other cell
types, express two different TNFRs, designated TNFR1
(CD120a) and TNFR2 (CD120b) [19]. Signaling is initi-
ated when ligand-occupied receptors recruit the binding
of intracellular adaptor proteins to the intracellular portions
of the receptor molecules (reviewed in [20,21]). Initially,
ligand-occupied TNFR1 binds TNF-receptor-associated
death-domain protein (TRADD) through interactions of
homologous regions, called ‘death domains’ (DDs),
expressed in both proteins [22]. The original DD was so
named because it was found in the death-inducing recep-
tor Fas as well as in an adaptor protein recruited to ligand-
occupied Fas, called Fas-associated DD protein (FADD).
The three-dimensional structure of the TNFR1 DD has
recently been solved by two separate groups of
researchers, and two interactive TRADD binding sites
have been defined [23,24]. Unoccupied TNFR1 associ-
ates with a DD-containing protein, called silencer of DDs
(SODD), which is displaced by TRADD upon TNF binding
[25]. Receptor-bound TRADD can recruit FADD through
DD interactions and thereby mimic the death-activation
responses of Fas [26].
TRADD recruitment also initiates the recruitment of two
other adaptor proteins that have been linked to activation
of NF-κB and for AP-1, namely receptor interacting protein
(RIP) and TNF-receptor-associated factor 2 (TRAF2). RIP
is a serine/threonine kinase that contains a DD that medi-
ates binding to TRADD [27]. The mechanism of action of
RIP is unclear; kinase-inactive RIP can function when over-
expressed, but this may involve recruitment of endoge-
nous RIP molecules with an intact kinase activity.
Thymocytes from knockout mice lacking RIP cannot acti-
vate NF-κB in response to TNF but can still respond to
TNF by activating AP-1 [28]. TRAF2 binds to the N-termi-
nal domain of TRADD, i.e. outside the DD [29]. TRAF2
contains an N-terminal RING domain, which is essential
for its signaling, a series of zinc fingers, and C-terminal
TRAF domains shared with other members of the TRAF
family. The TRAF domains mediate both self-association
and binding to adaptor proteins (e.g. TRADD). Unlike RIP,
TRAF2 has no known enzymatic activities (although RING
domains may act as E3 ubiquitin ligases) [30]. Embryonic
fibroblasts lacking TRAF2 show a partially impaired ability
of TNF to activate NF-κB and show complete loss of TNF-
induced activation of AP-1 [31]. (The incomplete effect of
TRAF2 deficiency may arise because of redundancy with
TRAF5 [32].) TRAF2 may indirectly contribute to NF-κB
activation by recruiting and/or stabilizing the interactions
of RIP with its downstream targets [33]. Overexpression
of either RIP or TRAF2 in wild-type cells can initiate both
NF-κB and AP-1 signaling independent of TNF, TNFR1, or
TRADD, possibly by driving association of adaptor pro-
teins in a nonphysiological manner.
The physiological downstream targets of RIP or TRAF2
remain uncertain. Both the NF-κB and the AP-1 pathways
are activated by members of the mitogen-activated-protein
kinase (MAPK) kinase kinase (MAP3K, also known as
MEKK) family. Experiments in gene-knockout embryonic
fibroblasts implicate MEKK-1 in the AP-1 pathway [34]
and MEKK3 in the NF-κB pathway [35] activated by TNF.
Several different MEKKs can phosphorylate and activate a
cytosolic enzymatic complex called IκB kinase (IKK) [36].
This multiprotein complex contains at least two active
kinases (IKK-α and IKK-β), as well as a regulatory protein
that lacks kinase activity, called IKK-γ, or NEMO. Studies
in gene-knockout animals point to IKK-β as the crucial
component that mediates TNF-induced phosphorylation of
cytosolic inhibitor of κB (IκB) proteins [37,38] and show
that IKK-γ (NEMO) is required for this response [39].
In unstimulated cells, IκB proteins normally sequester
dimeric NF-κB complexes in the cytosol, preventing their
entry into the nucleus where gene transcription occurs
[40]. In response to TNF, IκB proteins are phosphorylated
by IKK upon critical serine residues, and, once phosphory-
lated, are rapidly ubiquitinated and then degraded by the
cytosolic proteosome. This process occurs within
15 minutes of treating human umbilical-vein-derived
endothelial cells (HUVECs) with TNF. In HUVECs, TNF
causes degradation of IκB-α, -β, and -ε [41,42]. Once an
IκB protein is degraded, the associated NF-κB is free to
move from the cytosol to the nucleus and activate tran-
scription by binding to specific DNA sequences in the
enhancers of target genes. In HUVECs, TNF-activated
NF-κB is formed of homodimers or heterodimers involving
three different members of the Rel family, namely p50
(also called NF-κB1), p65 (also called Rel A), and c-Rel.
Homodimers of p50 appear to be constitutively present in
the nucleus and are not regulated by IκB degradation. A
recent report has suggested that IκB-α and IκB-β associ-
ate primarily with p50/p65 or p50/c-Rel heterodimers,
whereas IκB-ε associates primarily with p50/c-Rel or c-Rel
homodimers [42]. Minor variations in a κB-binding DNA
sequence may favor binding of one form of NF-κB over
another. In experiments using electrophoretic-mobility-shift
assay, the three E-selectin elements preferentially bind
p50/p65 heterodimers [43–45]. The VCAM-1 promoter
contains two tandem κB-binding sites that also appear to
preferentially bind p50/p65 [46,47]. In contrast, the
ICAM-1 promoter contains one κB element that may pref-
erentially bind p50/c-Rel heterodimers or c-Rel het-
erodimers [42,48].
AP-1 activation occurs when an MAP3K, probably
MEKK-1, phosphorylates and activates several MAP2Ks
(also known as MEKs), which, in turn, phosphorylate and
activate several MAPKs (also known as stress-activated
protein kinases, or SAPKs) such as c-Jun N-terminal
kinase (JNK)-1 and -2 and p38 MAPK [49]. JNK-1 and -2
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phosphorylate the transactivating domain of c-Jun, a com-
ponent of AP-1, and thereby enable AP-1 to activate gene
transcription. Normally, c-Jun forms heterodimers with
members of the Fos family, such as c-Fos or FosB, but
c-Jun also can heterodimerize with activating transcription
factor 2 (ATF2) to form a variant form of AP-1. TNF
increases the binding of c-Jun/ATF2 to a DNA sequence
in the E-selectin promoter [50]. Transfected E-selectin
promoter–reporter genes lacking the c-Jun/ATF2-binding
site are much less active than wild type [51], and E-
selectin transcription does not occur in mice lacking ATF2
[52]. The transcriptional potential of ATF2, like that of c-
Jun, can be increased by phosphorylation of its transacti-
vating domain, catalyzed by p38 MAP kinase. However,
while overexpression of a c-Jun mutant that cannot be
phosphorylated (or of dominant negative JNK isoforms)
will inhibit E-selectin transcription, a mutant form of ATF2
that cannot be phosphorylated is not inhibitory [51]. This
suggests that c-Jun/ATF2 is necessary for E-selectin tran-
scription but that only the c-Jun subunit needs to be phos-
phorylated for efficient gene transactivation. Both ICAM-1
and VCAM-1 also contain AP-1 binding sites (commonly
called tetrahydrophorbol response elements, or TREs) that
bind AP-1 in TNF-treated ECs [53,54]. In this case, AP-1
consists of c-Jun/cFos heterodimers. The significance of
the canonical TRE in the VCAM-1 promoter has been
questioned because this element is lacking in mice [54].
However, human and mouse VCAM-1 may not be regu-
lated in the same manner, and a role of AP-1 in VCAM-1
transcription has been demonstrated using
promoter–reporter genes in human ECs, although the site
where AP-1 appears to bind in the model is distinct from
the consensus TRE and is instead located between the
two κB-binding elements [55].
Although the activation of NF-κB and AP-1 may involve
divergent pathways, these factors interact in the nucleus
through concomitant binding of gene coactivators, such
as histone acetyl transferases like CREB-binding protein
(CBP), or p300 [56]. The steric positioning of individual
transcription factors bound to DNA, which permits coordi-
nate interactions with coactivators, may depend upon
DNA bending, controlled by proteins such as the high-
mobility-group protein HMG-Y1 [43–45]. The basic unit of
such coordinated complexes has been called an
‘enhanceosome’. The three NF-κB binding sites and the
AP-1 binding site in the E-selectin promoter appear to fit
this definition.
E-selectin transcription and AP-1 activation are both tran-
sient in TNF-treated HUVECs [57], but NF-κB activation is
not [41]. A decrease in phospho-c-Jun/ATF2, resulting
from shutting off of JNK activity, probably accounts for the
termination of E-selectin transcription [57]. Once the gene
turns off, E-selectin cannot be effectively reinduced by
TNF without a rest period of 18–24 hours. During the
refractory period, it can be reinduced by IL-1 or CD40
ligand, and reinduction correlates with the reactivation of
JNK. Since JNK activation is mediated by TRAF proteins
and since TNF, IL-1, and CD40 ligand all use distinct
TRAF proteins (although CD40 ligand does recruit TRAF2
and TRAF6 as well as TRAF3 and TRAF5), an attractive
explanation for receptor-specific desensitization is that
specific TRAFs are somehow selectively inactivated. TRAF
proteins contain RING domains that can act as ubiquitin
E3 ligases [30], and it is possible that ubiquitination is
involved in TRAF inactivation and is responsible for the
reduction of JNK and AP-1 activity. This speculation is
supported by the observation that TRAF activation by
CD30 in T cells is terminated by TRAF ubiquitination and
degradation [58].
In some cells, TNF signaling may involve signaling path-
ways in addition to those described above, including the
activation of phosphatidylinositol-3 kinase and protein
kinase B (also known as Akt) [59]; activation of neutral or
acidic sphingomyelinases to generate ceramide [60]; de
novo sphingosine-1 phosphate (S-1P) synthesis [61]; and
a Ras/Raf/ERK growth-control pathway [62]. My labora-
tory has shown that the Akt and ceramide pathways do
not contribute to adhesion molecule expression in ECs
[63,64]. It is possible that the S-1P and Ras pathways do
participate in ELAM regulation, but, if so, the biochemical
links to ELAM gene transcription are unknown.
The cell biology of TNF signaling in ECs
The biochemical view of TNF signaling described above is
well supported by genetic and molecular data. However,
my colleagues and I believe that it is an incomplete
description, because it does not consider the capacity of
cells to regulate interactions of receptors and adaptor pro-
teins through control of their subcellular localization. Much
of our recent work has focused upon this aspect of TNF
signaling. HUVECs have very little TNFR1 on their surface;
the predominant surface receptor is TNFR2 [65,66].
Although TNFR2 can directly bind TRAF2 (as well as
TRAF1), it does not activate expression of adhesion mole-
cules in these cells [19] (although it can do so, indepen-
dently of ligand, when overexpressed) [67]. However, the
presence of TNFR2 increases the cells’ sensitivity to TNF
[19], consistent with the hypothesis of ligand passing from
a higher-affinity (TNFR2) to a lower-affinity (TNFR1) recep-
tor [68].
When TNF binds to ECs, much of it is rapidly internalized.
Most of the internalized ligand follows a coated-
pit/coated-vesicle pathway, winding up in endosomal/lyso-
somal compartments [65]. TNFR2 shows a similar pattern
of internalization, and it is likely that most TNF uptake is
mediated via this nonsignaling receptor. Surprisingly, a
significant fraction of internalized TNF molecules end up
associated with mitochondria [69] and a third TNF-binding
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protein (of approximately 60 kDa) has been identified in
the inner membrane of this organelle [69]. The complete
identity of this molecule, the pathway by which TNF is
transported to the mitochondria, and the function, if any, of
mitochrondial TNF are still unknown.
In cultured HUVECs, as in many other cell types, the
majority of TNFR1 molecules are located within the Golgi
apparatus, retained there through an undefined inter-
action involving the DD [65,66]. Until recently, the cellular
and subcellular distributions of TNFR1 were known only
from studies of cultured cells. Interestingly, in our initial
analysis of a human tissue, namely the kidney, my
colleagues and I found that TNFR1 was confined mainly
to the Golgi apparatus of golmerular and peritubular
capillary ECs [70], consistent with findings in studies in
vitro (although the absence of TNFR1 in cell types other
than ECs was unexpected). The role of the Golgi popula-
tion of receptors is unknown. Plasma-membrane recep-
tors can be internalized to an ER-like compartment in
response to MAPK-mediated phosphorylation [71]. My
colleagues at Cambridge University and I have recently
found that Golgi receptors can be mobilized to appear on
the cell surface by stimulation of cultured ECs with hista-
mine (Jun Wang et al., unpublished observations).
When HUVECs are exposed to noxious stimuli, TNFR1 is
shed from the surface [72]. This response is mediated by
a protease inhibited by the compound TAPI (TACE pro-
tease inhibitor), and thus likely to be identical to TNF-α-
converting enzyme (TACE). Shedding of receptors both
desensitizes HUVECs to TNF [72] and serves as a source
for soluble receptor (sTNFR), a natural inhibitor of TNF
function [73]. The Golgi pool of receptors could thus be a
reservoir for replacing shed receptors on the surface or
could serve as a precursor pool for increasing the number
of shed receptors. Our recent observations indicate that
the same signals that mobilize receptors from the Golgi
apparatus also favor receptor shedding, supporting the
latter hypothesis (Jun Wang et al., unpublished observa-
tions). The importance of receptor shedding is highlighted
by the finding that deficiencies in shedding receptors due
to structural mutations in TNFR1 underlie TNFR-associ-
ated periodic syndrome (TRAPS), characterized by febrile
episodes related to overreaction to TNF [74].
Even though only a minority of TNFR1 molecules are
present on the plasma membrane, these molecules are
critically important, because they are the only population
that interacts with TRADD upon TNF treatment [75]. The
cellular compartment(s) in which FADD, RIP, and TRAF2
are recruited to the TNFR1/TRADD complex is unknown.
However, my colleagues and I and others have also
observed that treatments that reduce membrane traffick-
ing (e.g. endocytosis) also block TNF signaling [76,77],
and such observations imply that TNFR1 signaling com-
plexes move from the plasma membrane in order to signal
efficiently. My colleagues and I also have found that inter-
nalized receptors rapidly dissociate from TRADD, poten-
tially limiting signaling [76].
A recent idea in receptor function is that activated recep-
tors efficiently interact with adaptor proteins (and engage
in crosstalk with other receptors) only when the relevant
proteins are brought into proximity within cholesterol- and
sphingomyelin-rich patches of the plasma membrane
called lipid rafts [78,79]. In ECs and certain other cell
types, lipid rafts bind cytoskeletal scaffolding proteins
called caveolins [80]. Caveolin binding causes the rafts to
invaginate, forming specialized organelles known as cave-
olae. Although caveolae were first identified for their role in
initiating transcellular vesicular transport, they are now
(additionally) thought to facilitate signaling and permit
receptor crosstalk. It is thus noteworthy that in ECs,
TRAF2 is normally associated with caveolin-1 [67]. This
finding suggests that the TNFR1 signaling complex,
through binding of TRAF2, can be recruited via caveolin-1
to caveolae, where interactions with other signaling path-
ways may occur.
Concluding remarks
TNF-mediated induction of ELAM gene expression in vas-
cular ECs is a central event in inflammation. Over the past
10 years, a reasonably good biochemical model has been
developed of how TNF can activate two families of tran-
scription factors, namely NF-κB and AP-1, whose activa-
tion is necessary for expression of ELAM genes. Our
current focus of investigation is how this biochemical
model operates within the living ECs, where various inter-
active components may either be segregated or brought
together in response to ligand binding. The more com-
plete picture of TNF signaling, which is being developed
from these studies, may lead to new, more nuanced thera-
peutic approaches to regulating the inflammatory process.
Glossary of terms
ATF = activating transcription factor; DD = death domain;
ELAM = endothelial leukocyte adhesion molecule; FADD =
Fas-associated DD protein; HUVEC = human umbilical-
vein-derived endothelial cell; IKK = IκB kinase; JNK = c-Jun
N-terminal kinase; MAPK = mitogen-activated protein
kinase; MEK = MAPK kinase (also called MAP2K); MEKK =
MEK kinase (also called MAP3K); RIP = receptor inter-
acting protein; TRADD = TNF-receptor-associated death-
domain protein; TRAF = TNF-receptor-associated factor;
TRE = tetrahydrophorbol response element.
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